PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT05456503
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • [18F]-PI-2620 — DRUG
    Radiotracer

Study Details

The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

Key Dates

Start date
Sep 19, 2022
Status verified
Nov 2025
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
72 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Cognitively and neurologically normal adults (CN)
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Non-amnestic Alzheimer's Disease (AD)
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Frontotemporal lobar degeneration from tauopathy (FLTD-tau)
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Frontotemporal lobar degeneration from TDP-43 (FLTD-TDP)
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Frontotemporal lobar degeneration from mutation in the MAPT gene (genetic FLTD-tau)
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Frontotemporal lobar degeneration from mutation in the GRN gene or frame 72 of chromosome 9
    One PET imaging scan using the \[18F\]-PI-2620 tracer
  • Experimental: Amnestic Mild Cognitive Impairment Alzheimer's Disease (MCI/aAD)
    One PET imaging scan using the \[18F\]-PI-2620 tracer

Primary Outcome Measure

Whole brain SUVR [ Time Frame: Once during single PET CT ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Perelman Center for Advance MedicinePhiladelphiaPennsylvania19104
Dahlia Kamel
[email protected]
215-662-6134
David J Irwin, MD (PRINCIPAL_INVESTIGATOR)
Jeffrey S Philiips, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Perelman Center for Advance Medicine· Philadelphia, PA

Related Studies